Transcript
Page 1: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A687

DISCLOSURE INFORMATION

Research Presentations Financial Disclosure Statements

The International Society for Pharmacoeconomics and Outcomes Research asked all abstract contributors to disclose fi nancial support for their research. The following fi nancial support was declared:

Copyright © 2014, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

REFERENCE CODE

FINANCIAL SUPPORT

CN1 NoneCN2 Nucletron bv, Veenendaal, The NetherlandsCN3 CTMM, Eindhoven, The NetherlandsCN4 Bristol Myers Squibb, Uxbridge, UKCP1 Genzyme, Naarden, The Netherlands; BioMarin, Dublin, IrelandCP2 NoneCP3 The Cochrane Collaboration, Oxford, UKCP4 NoneCV1 Novartis, Basel, SwitzerlandCV2 Amgen, Inc., Thousand Oaks, CA, USACV3 Novartis Pharma B.V., Arnhem, The NetherlandsCV4 Roche Products Ltd., Welwyn Garden City, UKDI1 NoneDI2 National Institute of Health, Bathesda, MD, USADI3 Abbott Diabetes Care, ROME, ItalyDI4 Instituto de Salud Carlos III PFIS-11 FIS ISCIII (320), Madrid,

Spain; DIUE, Generalitat de Catalunya (2009 SGR 1095), Barcelona, Spain; Instituto de Salud Carlos III FEDER PI13/00506, Madrid, Spain

HC1 NoneHC2 Decision Resources Group, Burlington, MA, USAHC3 LIF, Stockholm, Sweden; National Center for Priority Setting in

Health Care, Linköping, SwedenHC4 ICON, London, UKHS1 Janssen, Beerse, BelgiumHS2 NoneHS3 NoneHS4 NoneMA1 The Netherlands Organisation for Health Research and

Developmend (ZonMW), The Hague, The NetherlandsMA2 Kantar Health, Epsom, UKMA3 NoneMA4 NoneMO1 NoneMO2 Novartis Pharma AG, Basel, SwitzerlandMO3 Medical Research Council, Bristol, UK; Mapi, Houten,

The NetherlandsMO4 NoneNI1 NoneNI2 NoneNI3 NoneNI4 NonePCN1 Eisai Inc., Woodcliff Lake, NJ, USAPCN2 NonePCN4 NonePCN5 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN6 Genentech, San Francisco, CA, USAPCN7 Bristol-Myers Squibb, Rueil-Malmaison, FrancePCN8 Boehringer Ingelheim International, Ingelheim, GermanyPCN9 Bristol-Myers Squibb, Plainsboro, NJ, USAPCN10 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN11 F. Hoffmann - La Roche AG, Basel, SwitzerlandPCN12 Janssen, Beerse, BelgiumPCN13 NonePCN14 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN15 Sobi, Solna, SwedenPCN16 Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UKPCN20 Eli Lilly and Company, Windlesham, UKPCN21 Janssen-Cilag, Neuss, GermanyPCN22 National Institute of Health Research, London, UKPCN23 Janssen-Cilag, High Wycombe, UKPCN24 Janssen-Cilag BV, Tilburg, The Netherlands; Janssen-Cilag AB,

Sollentuna, Sweden; Janssen-Cilag GMBH, Neuss, GermanyPCN25 Novartis, Basel, SwitzerlandPCN26 Novartis, Moscow, RussiaPCN27 Roche Farmacêutica Quimica, Amadora, PortugalPCN28 NonePCN29 GlaxoSmithKline, Zeist, The NetherlandsPCN30 IPSEN, Boulogne-Billancourt, FrancePCN31 NonePCN32 NonePCN33 Bristol-Myers Squibb, Rueil Malmaison, FrancePCN34 NonePCN35 NonePCN36 None

REFERENCE CODE

FINANCIAL SUPPORT

PCN37 NonePCN38 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN39 Roche Farmacêutica Quimica, Amadora, PortugalPCN40 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN41 Sanofi -Aventis, Warsaw, PolandPCN42 Bayer Healthcare Pharmaceuticals, Inc., Wayne, NJ, USAPCN43 NonePCN44 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAPCN45 NonePCN46 Janssen, Sao Paulo, BrazilPCN47 Meda Pharma, Frankfurt, GermanyPCN48 Pfi zer, Mexico, MexicoPCN49 NonePCN50 NonePCN51 NonePCN52 NonePCN53 Eisai, Woodcliff Lakes, NJ, USAPCN54 Green Cross, Yong-In, South KoreaPCN55 Pfi zer, Inc., São Paulo, BrazilPCN56 Genomic Health, Geneva, SwitzerlandPCN58 GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi

izdelki, Ljubljana, Slovenia, Ljubljana, SloveniaPCN59 KWF Cancer Research, Amsterdam, The NetherlandsPCN60 Teva Pharmaceutical, Philadelphia, PA, USAPCN61 National Cancer Institute, Boulogne Billancourt, FrancePCN62 French National Cancer Institute, Boulogne Billancourt, FrancePCN63 Roche Products Limited, Welwyn Garden City, UKPCN64 MSD Italy, Rome, ItalyPCN65 NonePCN66 NonePCN67 NonePCN68 GlaxoSmithKline Slovakia s.r.o, Bratislava, Slovak RepublicPCN69 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN70 Laboratórios Pfi zer Lda, Lisbon, PortugalPCN71 NonePCN72 Pfi zer, Mexico, MexicoPCN73 NonePCN74 NonePCN75 NonePCN76 NonePCN77 NonePCN78 NonePCN79 Health Research Board, Dublin, IrelandPCN80 NonePCN81 2Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San

Francisco, CA, USAPCN82 NonePCN83 Sanofi Pasteur MSD, Maidenhead, UKPCN84 Eisai, Woodcliff Lake, NJ, USAPCN85 Pfi zer, New York, NY, USAPCN86 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,

GermanyPCN87 UERJ, Rio de Janeiro, Brazil; UFF, Niterói, BrazilPCN88 Pfi zer, Mexico, MexicoPCN89 The Ministry of Science and Education of the Republic of Serbia

for Grant N°175014, Belgrade, Serbia and MontenegroPCN90 Amgen Inc., Thousand Oaks, CA, USAPCN91 NonePCN92 NonePCN93 Innovative Medicine Initiative, Brussels, BelgiumPCN94 Department of Health, Canberra, AustraliaPCN95 the Center for Translational Molecular Medicine, Eindhoven,

The NetherlandsPCN96 NonePCN97 Norgine Ltd., Uxbridge, UKPCN98 GlaxoSmithKline S.R.L., Bucharest, RomaniaPCN99 NonePCN100 Productos Roche, Bogota, ColombiaPCN101 BMS Spain, Madrid, SpainPCN102 NonePCN103 Janssen, Panama, PanamaPCN104 Novartis, Camberley, UKPCN105 Genesis Pharma, Athens, GreecePCN106 Amgen, Zug, SwitzerlandPCN107 GSK, Tres Cantos (Madrid), Spain

Page 2: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A688 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PCN108 AstraZeneca, Mexico City, MexicoPCN109 GlaxoSmithKline, Mississauga, ON, CanadaPCN110 Amgen, Athens, GreecePCN111 Amgen, Athens, GreecePCN112 Roche Hungary, Budapest, HungaryPCN113 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN114 NonePCN115 Novartis Pharmaceuticals, East Hanover, NJ, USAPCN116 GlaxoSmithKline Biological S.A., Rixensart, Belgium;

GlaxoSmithKline Slovakia, Bratislava, Slovak RepublicPCN117 Novartis, Camberley, UKPCN118 NonePCN119 BMBF, Bonn, GermanyPCN120 Janssen, Panama, PanamaPCN121 Janssen, panama, PanamaPCN122 Novartis, Moscow, RussiaPCN123 Covance Inc., London, UKPCN124 NonePCN125 NonePCN126 NonePCN127 NonePCN128 NonePCN129 Helmholtz Zentrum München, Neuherberg, GermanyPCN130 Sanofi Pasteur MSD, Lyon, FrancePCN131 NonePCN132 Takeda Pharmaceuticals, Zurich, Switzerland; T.I. Salud, Mexico

City, MexicoPCN133 NonePCN134 NonePCN135 NonePCN136 Pfi zer China, Shanghai, ChinaPCN137 University of Jordan, Amman, JordanPCN138 Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UKPCN140 NonePCN141 NonePCN142 Psicofarma, Mexico City, MexicoPCN143 Oncotyrol, Innsbruck, AustriaPCN144 Oncotyrol, Innsbruck, AustriaPCN145 Takeda Pharma, Solna, SwedenPCN146 Laboratórios Pfi zer Lda., Porto Salvo, PortugalPCN147 NonePCN148 Carl-Zeiss, Oberkochen, GermanyPCN149 NonePCN150 Novartis, UKPCN151 Roche Hellas, Athens, GreecePCN152 Roche Pharmaceuticals, São Paulo, BrazilPCN153 NonePCN154 Grindex, Moscow, RussiaPCN155 Mundipharma GesmbH. Austria - organization unit Czech

Republic, Prague, Czech RepublicPCN156 Boehringer Ingelheim, Alkmaar, The NetherlandsPCN157 National Institute of Health Research, London, UKPCN158 Celgene International Sarl, Boudry, SwitzerlandPCN159 NonePCN160 NonePCN161 Celgene, Summit, NJ, USAPCN162 NonePCN163 Bristol-Myers Squibb, Rueil Malmaison, FrancePCN164 NonePCN165 NonePCN166 AdRes, Turin, ItalyPCN167 German Federal Ministry of Education and Research, Berlin,

GermanyPCN168 AstraZeneca UK Ltd., Luton, UKPCN169 Amgen Inc., Thousand Oaks, CA, USAPCN170 CTMM, Eindhoven, The NetherlandsPCN171 NonePCN172 NonePCN173 Personalized Medicine Partnership for Cancer (PMPC),

Montreal, QC, CanadaPCN174 Amgen Inc., Thousand Oaks, CA, USAPCN175 NonePCN176 NonePCN177 UBC, Dorval, CanadaPCN178 AstraZeneca, Alderley Park, UKPCN179 Oxford PharmaGenesis Ltd., Tubney, Oxford, UKPCN180 Eisai Inc., Woodcliff Lake, NJ, USAPCN181 GILEAD, London, UKPCN182 AstraZeneca, Macclesfi eld, UKPCN183 DIUE de la Generalitat de Catalunya (2009 SGR 1095), Barcelona,

Spain; Catalan Agency for Health Information, Assessment and Quality (grant AATRM 436/05/2008), Barcelona, Spain

PCN184 Roche, Boulogne Billancourt, FrancePCN185 National Institute of public health and the environment, Bilthoven,

The NetherlandsPCN186 Institut de Recherche Pierre Fabre, Boulogne-Billancourt, FrancePCN187 None

REFERENCE CODE

FINANCIAL SUPPORT

PCN188 NonePCN189 NonePCN190 NIHR School for Primary Care Research, London, UKPCN191 Astellas Pharma a/s, Kastrup, DenmarkPCN192 NonePCN193 NonePCN194 Amgen (Europe) GmbH, Zug, SwitzerlandPCN195 NonePCN196 The Netherlands Organisation for Health Research and

Development, The Hague, The Netherlands; Roche The Netherlands, Woerden, The Netherlands; Pfi zer The Netherlands, Capelle a/d IJssel, The Netherlands

PCN197 Genentech, South San Francisco, CA, USAPCN198 Takeda, Roskilde, DenmarkPCN199 GlaxoSmithKline, Cambridge, UKPCN200 LifeCell Corporation, Bridgewater, NJ, USAPCN201 Ipsen Pharma GmbH, Ettlingen, GermanyPCN202 Janssen Pharmaceuticals, Neuss, GermanyPCN203 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am

Rhein, GermanyPCN204 Health Research Board, Dublin, IrelandPCN205 Roche, Basel, SwitzerlandPCN206 Medivation, Inc., San Francisco, CA, USA; Astellas Pharma Global

Development, Inc., Northbrook, IL, USAPCN207 NonePCN208 NonePCN209 NonePCN210 University of the Basque Country, UPV / EHU, Basque Country,

SpainPCN211 NonePCN212 NonePCN213 NIHR, Leeds, UKPCN214 NonePCN215 NonePCN216 NonePCN217 NonePCN218 Main Association of Austrian Health Security Institutions, Vienna,

AustriaPCN219 Eli Lilly Italy, Florence, ItalyPCN220 NonePCN221 Roche F.Hoffmann-La Roche Ltd., Moscow, RussiaPCN222 Novartis Hellas, Metamorfosi, Attica, Athens, GreecePCN223 NonePCN224 NonePCN225 Decision Resources Group, Burlington, MA, USAPCN226 NonePCN227 Eli Lilly and Company, Indianapolis, IN, USAPCN228 NonePCN229 NonePCN230 NonePCN231 NonePCN232 AstraZeneca, Zoetermeer, The NetherlandsPCN233 MUSC Medication Safety Program, Charleston, SC, USAPCN234 Genentech, Inc., South San Francisco, CA, USAPCN235 NonePCN236 GE Healthcare, Riyadh, Saudi ArabiaPCN237 NonePCN238 Amgen CEE Headquarters, Vienna, AustriaPCN239 NonePCN240 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN241 NonePCN242 NonePCN243 Boehringer Ingelheim, Bracknell, UKPCN244 NonePCN245 Amgen CEE Headquarters, Vienna, AustriaPCN246 NonePCN247 Alliance Life Sciences Consulting Group, Somerset, NJ, USAPCN248 Roche Pharma AG, Grenzach-Wyhlen, GermanyPCN249 NonePCN250 NonePCN251 NonePCN252 Roche, Welwyn Garden City, UKPCN253 IMS Consulting Group, Munich, GermanyPCN254 NonePCN255 NonePCN256 NonePCN257 NonePCN258 NonePCN259 NonePCN260 Costello Medical Consulting, Cambridge, UKPCN262 NonePCN263 Pharmaceutical Research and Manufacturers of America,

Washington, DC, USAPCN264 São Paulo Research Foundation (FAPESP), Sao Paulo, BrazilPCN265 NonePCN266 Quintiles Consulting, Reading, UKPCN267 None

Page 3: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A689

REFERENCE CODE

FINANCIAL SUPPORT

PCN268 Evidera, London, UKPCN269 European Commission, Brussels, The NetherlandsPCN270 Ministry of Health and Welfare, Sejong, South KoreaPCN271 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,

GermanyPCN272 NonePCN273 Genomic Health, Inc., Redwood City, CA, USAPCN275 The Netherlands Organisation for Health Research and

Development, the Hague, The NetherlandsPCN276 NonePCN277 Oncotyrol, Innsbruck, Austria; Austrian Federal Ministries

of BMVIT/BMWFJ, Vienna, Austria; Tiroler Zukunftsstiftung/Standortagentur Tirol, Innsbrucker, Austria

PCN278 NonePCN279 ZonMw, Den Haag, The NetherlandsPCN280 AstraZeneca, London, UKPCN281 NonePCV1 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV2 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV3 NonePCV4 U.S. Food and Drug Administration, Silver Spring, MD, USAPCV5 NonePCV6 Bayer Pharma AG, Berlin, GermanyPCV7 NonePCV8 NonePCV9 Amgen, Thousand Oaks, CA, USAPCV10 Medtronic Inc., Santa Rosa, CA, USAPCV11 Medtronic, Minneapolis, MN, USAPCV12 NonePCV14 BMS, Princeton, NJ, USA; Pfi zer, New York, NY, USAPCV15 National Evidence-based Healthcare Collaborating Agency, Seoul,

South KoreaPCV16 Proteus Digital Health, Redwood City, CA, USAPCV17 AstraZeneca, Mölndal, SwedenPCV18 Boehringer Ingelheim, Paris, FrancePCV19 Pfi zer Ltd., Surrey, UKPCV20 NonePCV21 Bayer Hispania, Barcelona, SpainPCV22 Pierre Fabre Médicament, Boulogne, FrancePCV23 Merck Shape & Dohme, Hoddesdon, UKPCV24 NonePCV25 Bristol-Myers Squibb, Princeton, NJ, USAPCV26 BMS, Rueil Malmaison, FrancePCV27 National Heart, Lung, and Blood Institute, Bethesda, MD, USA;

American Heart Association, Dallas, TX, USAPCV28 Menarini, Florence, ItalyPCV29 NonePCV30 Eli Lilly and Company, Indianopolis, IN, USAPCV31 RAGS, Selangor, MalaysiaPCV34 NonePCV35 Amgen Inc., Thousand Oaks, CA, USAPCV36 Pfi zer, S.L.U., Madrid, SpainPCV37 Servier Poland Sp. z o.o., Warsaw, PolandPCV38 Proteus Digital Health, Redwood City, CA, USAPCV39 Bristol-Myers Squibb Italy, Rome, Italy; Pfi zer Italia, Rome, ItalyPCV40 NonePCV41 Abbott Hellas, Athens, GreecePCV42 Ipsen Pharma, Ettlingen, GermanyPCV43 NonePCV44 NonePCV45 The Medicines Company, Parsippany, NJ, USAPCV46 NonePCV47 NonePCV48 Abbott Vascular, Rungis, FrancePCV49 diaDexus, San Francisco, CA, USAPCV50 Heart and Stroke Foundation of Canada, Toronto, ON, CanadaPCV51 NonePCV52 NonePCV53 Sorin Group Italia, Milano, ItalyPCV54 National Health and Medical Research Council, Canberra,

AustraliaPCV55 NonePCV56 Medtronic, Inc., Mounds View, MN, USAPCV57 Medtronic, Sesto S.Giovanni, Italy; Medtronic, Meerbusch,

Germany; Medtronic, Madrid, Spain; Medtronic, Warsaw, Poland; Medtronic, Maastricht, The Netherlands

PCV58 Ministry of Health of the Czech Republic, Prague, Czech RepublicPCV59 Boehringer-Ingelheim France, Paris, FrancePCV60 Bristol-Myers Squibb, Rueil-Malmaison, France; Pfi zer, Paris,

FrancePCV61 CSL Behring, King of Prussia, PA, USAPCV62 Medtronic Iberia, Madrid, SpainPCV63 NonePCV64 Novartis Pharma AG, Basel, SwitzerlandPCV65 NonePCV66 Gedeon Richter, Budapest, HungaryPCV67 BMBF, Bonn, Germany

REFERENCE CODE

FINANCIAL SUPPORT

PCV68 Medtronic spa, Sesto San Giovanni (MI), ItalyPCV69 Novartis, Dublin, IrelandPCV70 CSL Behring, King of Prussia, PA, USAPCV71 NonePCV72 CTMM, Eindhoven, The Netherlands; Dutch Heart Foundation,

The Hague, The Netherlands; Dutch Organisation for Health Research and Healthcare Innovation, The Hague, The Netherlands

PCV74 NonePCV75 Institute of Cardiology, Warsaw, PolandPCV76 Medtronic Italia S.p.A., Sesto San Giovanni, ItalyPCV77 NonePCV78 Baxter, Utrecht, The NetherlandsPCV79 Boehringer-Ingelheim, Bogota, ColombiaPCV80 Vifor Pharma, Athens, GreecePCV81 NonePCV82 Servier, Madrid, SpainPCV83 Bristol-Myers Squibb Italy, Rome, Italy; Pfi zer Italia, Rome, ItalyPCV84 University Sains Malaysia, Penang, MalaysiaPCV85 NonePCV86 AstraZeneca, Hong Kong, Hong KongPCV87 National Institutes of Health, Rockville, MD, USAPCV88 Bristol-Myers Squibb Italy, Rome, Italy; Pfi zer Italia, Rome, ItalyPCV89 CTMM, Eindhoven, The Netherlands; Dutch Heart Foundation,

The Hague, The NetherlandsPCV90 BMS, Princeton, NJ, USA; Pfi zer, New York, NY, USAPCV91 Grant of Ministry of Health, IGA NT11532 "Hodnoceni

zdravotnickych prostredku", Prague, Czech RepublicPCV92 NonePCV93 Ferrer, Barcelona, SpainPCV94 National Clinical Guideline Centre, London, UKPCV95 Boehringer Ingelheim GmbH, Ingelheim amRhein, GermanyPCV96 Boehringer Ingelheim GmbH, Ingelheim am Rhein, GermanyPCV97 Bristol-Myers Squibb, Pfi zer, Moscow, RussiaPCV98 Boehringer Ingelheim, Ingelheim, GermanyPCV99 Medical Research & Innovation LP, Thessaloniki, Greece;

Novartis Hellas, Athens, GreecePCV100 National Institute for Health Research (NIHR), HTA Programme,

London, UKPCV101 Medtronic Trading NL BV, Heerlen, The NetherlandsPCV102 NonePCV103 Cardiome, Vancouver, CanadaPCV104 W.L.Gore & Associati S.r.l., Barcelona, SpainPCV105 Gedeon Richter, Budapest, HungaryPCV106 Servier Poland Sp. z o.o., Warsaw, PolandPCV107 LipoScience, Raleigh, NC, USAPCV108 Astrazeneca, Madrid, SpainPCV109 National Evidence-based Healthcare Collaborating Agency, Seoul,

South KoreaPCV110 Amgen, Inc., Thousand Oaks, CA, USAPCV111 Amgen, Inc., Thousand Oaks, CA, USAPCV112 Sanofi -Aventis Deutschland GmbH, Berlin, GermanyPCV113 NonePCV114 Nuffi c agency, The Hague, The NetherlandsPCV115 National Health Insurance Service, Seoul, South KoreaPCV116 Novartis Pharma AG, Basel, SwitzerlandPCV117 Poznan University of Medical Sciences, Poznan, PolandPCV118 Novartis Pharma AG, Basel, SwitzerlandPCV119 Amgen Inc., Thousand Oaks, CA, USAPCV120 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV121 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV122 NonePCV123 NonePCV124 NonePCV125 NonePCV126 NonePCV127 CVS, Woonsocket, RI, USAPCV128 Belgian Stroke Council, Hasselt, BelgiumPCV129 NonePCV130 Servier, Paris, FrancePCV131 Bayer Vital GmbH, Leverkusen, GermanyPCV132 Department of Health, Vitoria-Gasteiz, Spain; FIS, Madrid, SpainPCV133 Bristol-Myers Squibb, Princeton, NJ, USAPCV134 NonePCV135 Daiichi Sankyo Europe, Munich, GermanyPCV136 Pfi zer, Istanbul, TurkeyPCV137 NonePCV138 Poznan University of Medical Sciences, Poznan, PolandPCV139 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV140 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV141 NonePCV142 Amgen, Inc., Thousand Oaks, CA, USAPCV143 Bayer Healthcare Co. Ltd., Beijing, ChinaPCV144 Bayer Healthcare Co. Ltd., Beijing, ChinaPCV145 The Netherlands Organization for Health Research and

Development, The Hague, The NetherlandsPCV146 None

Page 4: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A690 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PCV147 NonePCV148 NonePCV149 NonePCV150 Pfi zer Health Research Foundation, Tokyo, JapanPCV151 Institute for Health Economics and Policy, Tokyo, JapanPCV152 German Federal Ministry of Education and Research (BMBF),

Berlin, GermanyPCV153 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,

GermanyPCV154 NonePCV155 HSE Medicines Management Programme, Dublin, IrelandPCV156 NonePCV157 NonePCV158 Mckinsey & Co, London, UKPCV159 NonePCV160 NonePCV161 Bristol-Myers Squibb, Princeton, NJ, USA; Pfi zer, New York, NY,

USAPCV162 Amgen, Inc., Thousand Oaks, CA, USAPCV163 FCT PTDC/SAU-ESA/103511/2008, Lisbon, Portugal;

Pest-OE/MAT/UI0006/2011, Lisbon, PortugalPCV164 The European Health Technology Institute for Socio-Economic

Research, Brussels, BelgiumPCV165 NonePCV166 Novartis, Athens, GreecePCV167 University of Geneva Hospitals, Geneva, SwitzerlandPCV168 Heart and Stroke Foundation of Canada, Toronto, ON, Canada;

Alberta Provincial Stroke Strategy, Edmonton, AB, CanadaPCV170 Heart and Stroke Foundation of Canada, Toronto, ON, Canada;

Alberta Provincial Stroke Strategy, Edmonton, ON, CanadaPCV171 UBC: An Express Scipts Company, Montreal, CanadaPCV172 Medtronic Iberia, Madrid, SpainPCV173 Abbott Nutrition, Columbus, OH, USAPCV174 Orbus Neich, Hong Kong, ChinaPCV175 Boehringer Ingelheim France, Paris, FrancePCV176 NonePCV177 NonePCV178 Merck Sharp & Dohme, Oeiras, PortugalPCV179 Novartis Pharma AG, Basel, SwitzerlandPCV180 NonePCV181 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV182 Bristol-Myers Squibb, New York, NY, USAPCV183 Amgen, Zug, SwitzerlandPDB1 Merck Sharpe & Dohme, Oeiras, PortugalPDB2 Merck Sharp & Dohme, Oeiras, PortugalPDB3 Novo Nordisk Farma, Espoo, FinlandPDB4 Merck Sharp & Dohme, Oeiras, PortugalPDB5 Boehringer-Ingelheim, Ingelheim am Rheim, GermanyPDB6 Boehringer-Ingelheim, Ingelheim am Rheim, GermanyPDB7 Boehringer-Ingelheim, Ingelheim am Rheim, GermanyPDB8 Bayer HealthCare AG, Moscow, RussiaPDB9 NonePDB11 NonePDB12 Bristol-Myers Squibb, New York, NY, USAPDB13 Gt, jj, AlbaniaPDB14 NonePDB15 NonePDB17 Janssen Research & Development, Beerse, BelgiumPDB18 MSD, Courbevoie, FrancePDB19 Eli Lilly and Company, Windlesham, UKPDB20 Qatar National Research Fund, Doha, QatarPDB21 NonePDB22 Sanofi , Paris, FrancePDB23 Novartis Farmaceutica, Barcelona, SpainPDB24 NonePDB25 Becton, Dickinson and Company, Shanghai, ChinaPDB26 Novartis, Barcelona, SpainPDB27 Pharma Industry Finland, Helsinki, FinlandPDB28 Boehringer Ingelheim Pharma GmbH & Co. KG,

Ingelheim am Rhein, GermanyPDB29 NonePDB30 Novo Nordisk B.V., Alphen a/d Rijn, The NetherlandsPDB31 Merck Sharp & Dohme, Oeiras, PortugalPDB32 NonePDB33 Astra Zeneca, Sofi a, BulgariaPDB34 Takeda Pharmaceuticals, Zurich, SwitzerlandPDB35 Bayer HealthCare AG, Moscow, RussiaPDB36 Ethicon Global Surgery, Cincinnati, OH, USAPDB37 AstraZeneca, Södertälje, SwedenPDB38 Pfi zer, S.L.U., Madrid, SpainPDB39 EMD Serono, Inc., Rockland, MA, USAPDB40 ResMed Germany Inc., Martinsried, GermanyPDB41 NonePDB42 NonePDB43 Abbot Diabetes Care, Madrid, SpainPDB44 Abbott Diabetes Care, Madrid, SpainPDB45 Merck Sharp & Dohme, Oeiras, Portugal

REFERENCE CODE

FINANCIAL SUPPORT

PDB46 Novartis, Barcelona, SpainPDB47 Food and Health Bureau, Hong Kong, ChinaPDB48 NonePDB49 Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, ChinaPDB50 NonePDB51 Sanofi , Madrid, SpainPDB52 NonePDB53 NonePDB54 NonePDB55 NonePDB56 Independant Health Insurance Fund, Brussels, BelgiumPDB57 NonePDB58 NonePDB59 BC Pharma B.V., Moscow, RussiaPDB60 Becton, Dickinson and Company, Shanghai, ChinaPDB61 NonePDB62 Janssen A/S, Birkerød, DenmarkPDB63 Novo Nordisk, Madrid, SpainPDB64 Novo Nordisk, Madrid, SpainPDB65 NonePDB66 AstraZeneca UK, Luton, UKPDB67 AstraZeneca UK, Luton, UKPDB68 Janssen A/S, Birkerød, DenmarkPDB69 Janssen, Paris, FrancePDB70 AstraZeneca plc, Molndal, SwedenPDB71 Janssen, High Wycombe, UKPDB72 Medtronic, Tolochenaz, SwitzerlandPDB73 AstraZeneca UK, Luton, UKPDB74 Novo Nordisk, Athens, GreecePDB75 Janssen A/S, Birkerød, DenmarkPDB76 Janssen-Cilag Ltd., Dublin, IrelandPDB77 Janssen-Cilag Ltd., Dublin, IrelandPDB78 Janssen A/S, Birkerød, DenmarkPDB79 Medtronic, Tolochenaz, SwitzerlandPDB80 National Board of Health, Copenhagen, DenmarkPDB81 Janssen-Cilag Ltd., Dublin, IrelandPDB82 Janssen, Warsaw, PolandPDB84 BC Pharma B.V., Moscow, RussiaPDB85 Janssen A/S, Birkerød, DenmarkPDB86 National Institute for Health Research, London, UKPDB87 AstraZeneca UK Ltd., Luton, UKPDB88 AstraZeneca UK Ltd., Luton, UKPDB89 AstraZeneca UK Ltd., Luton, UKPDB90 NonePDB91 Novartis Farmaceutica, Barcelona, SpainPDB92 Medtronic International Trading Sarl, Tolochenaz, SwitzerlandPDB93 Medtronic International Trading Sarl, Tolochenaz, SwitzerlandPDB94 NonePDB95 AstraZeneca UK Ltd., Luton, UKPDB96 Ipsen, Athens, GreecePDB97 MSD, ItalyPDB98 AstraZeneca UK Ltd., Luton, UKPDB99 Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USAPDB100 Astra Zeneca, Levent-İstanbul, TurkeyPDB101 AstraZeneca, Madrid, SpainPDB102 NonePDB103 NIHR, London, UKPDB104 AstraZeneca, Madrid, SpainPDB105 AstraZeneca, Madrid, SpainPDB106 Otsuka Pharmaceutical Europe Ltd., Wexham, UKPDB107 Boehringer Ingelheim, Ingelheim am Rhein, GermanyPDB108 Abbott Diabetes Care, Alameda, CA, USAPDB109 Janssen, Warszawa, PolandPDB110 Boehringer Ingelheim, Ingelheim am Rhein, GermanyPDB111 National Science Centre, Cracow, PolandPDB112 Eli Lilly, Toronto, ON, Canada; Becton Dickinson, Mississauga,

ON, Canada; Novo Nordisk, Mississauga, ON, Canada; Sanofi , Laval, QC, Canada

PDB113 Allergan, Roma, ItalyPDB114 NonePDB115 Merck Sharp & Dohme, Oeiras, PortugalPDB116 Biodel Inc., Danbury, CT, USAPDB117 Merck Sharp & Dohme, Oeiras, PortugalPDB118 Merck Sharp & Dohme, Whitehouse Station, NJ, USAPDB119 Medtronic, Milano, ItalyPDB120 Merck Sharp & Dohme, Whitehouse Station, NJ, USAPDB121 Merck Sharp & Dohme, Whitehouse Station, NJ, USAPDB122 NonePDB123 NonePDB124 Otsuka Pharmaceutical Europe Ltd., Wexham, UKPDB125 Eli Lilly and Company, Indianpolis, IN, USAPDB126 NonePDB127 NonePDB128 Boehringer Ingelheim, Ingelheim, GermanyPDB129 Novo Nordisk Limited, Copenhagen, DenmarkPDB130 AstraZeneca, Hamburg, GermanyPDB131 AstraZeneca, Hamburg, Germany

Page 5: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A691

REFERENCE CODE

FINANCIAL SUPPORT

PDB132 Ipsen, Boulogne Billancourt, FrancePDB133 Novartis Farmaceutica, Barcelona, SpainPDB134 NonePDB135 NonePDB136 Novartis, Basel, SwitzerlandPDB137 Novartis Hellas SA, Metamorfosis, GreecePDB138 Novo Nordisk IO, Zurich, SwitzerlandPDB139 Janssen-Cilag A/S, Birkerød, DenmarkPDB140 NonePDB141 Novartis Hellas SA, Metamorfosis, GreecePDB142 NonePDB143 NonePDB144 Novo Nordisk Hellas Ltd., Athens, GreecePDB145 Novo Nordisk Hellas Ltd., Athens, GreecePDB146 NonePDB147 Truven Health Analytics, Bethesda, MD, USAPDB148 Novartis Hungary, Budapest, HungaryPDB149 NonePDB150 NonePDB151 Medtronic Inc., Istanbul, TurkeyPDB152 NonePDB154 NonePDB155 Charles University in Prague, Hradec Kralove, Czech RepublicPDB156 GlaxoSmithKline, London, UKPDB157 AstraZeneca, Mölndal, SwedenPDB158 NonePDB159 Biodel Inc., Danbury, CT, USAPDB160 MSD Ltd., Hoddesdon, UKPDB161 Takeda UK Ltd., London, UKPDB162 NonePDB163 NonePDB164 NonePDB165 NonePDB166 NonePDB167 NonePDB169 IHS, Englewood, CO, USAPDB170 Ministry of Health and Welfare, Sejong-si, South KoreaPDB171 NonePDB172 Merck Sharp & Dohme Ltd., Hoddesdon, UKPDB173 Bristol-Myers Squibb, New York, NY, USAPDB174 Roche Diagnostics GmbH, Mannheim, GermanyPGI1 NonePGI2 NonePGI3 Merck, Whitehouse Station, NJ, USAPGI4 Pfi zer Japan Inc., Tokyo, JapanPGI5 Leona M. and Harry B. Helmsley Charitable Trust,

New York, NY, USAPGI6 Merck, Whitehouse Station, NJ, USAPGI7 NonePGI8 Egis Pharmaceuticals PLC, Budapest, HungaryPGI9 NRF, Pretoria, South AfricaPGI10 Janssen, Sao Paulo, BrazilPGI11 Bristol-Myers Squibb, Rueil-Malmaison, FrancePGI12 Bristol-Myers Squibb, Rueil-Malmaison, FrancePGI13 AstraZeneca, London, UKPGI14 Laboratorios Almirall, S.A., Barcelona, SpainPGI15 NonePGI16 Almirall, London, UKPGI17 Barking, Havering and Redbridge University Hospitals NHS Trust,

Queen’s Hospital, Romford, UKPGI18 Almirall S.A., Barcelona, SpainPGI19 MSD Pharmaceuticals, Moscow, RussiaPGI20 Sucampo, Zug, SwitzerlandPGI21 Almirall, Lisbon, PortugalPGI22 Roche, Monza, ItalyPGI23 Gilead, Lisbon, PortugalPGI24 Johnson&Johnson LLC, Moscow, RussiaPGI25 NonePGI26 Gilead, Istanbul, TurkeyPGI27 Novartis, Basel, SwitzerlandPGI28 NonePGI29 NonePGI30 Gilead Sciences, Tokyo, JapanPGI31 NonePGI32 NonePGI33 Gilead Pharmaceutical, London, UKPGI34 AbbVie, North Chicago, IL, USAPGI35 The Royal Golden Jubilee Ph.D. Program, Bangkok, ThailandPGI36 AstraZeneca, London, UKPGI37 Sucampo, Zug, SwitzerlandPGI38 Lumbardy region, Milan, ID, ItalyPGI39 NonePGI40 Merck, Whitehouse Station, NJ, USAPGI41 NonePGI42 Forest Research Institute, Jersey City, NJ, USA; Ironwood

Pharmaceuticals, Inc., Cambridge,, MA, USAPGI43 None

REFERENCE CODE

FINANCIAL SUPPORT

PGI44 AbbVie, Campoverde di Aprilia (LT), ItalyPGI45 Laboratorios Almirall, S.A., Barcelona, SpainPGI46 Bristol-Myers KK, Tokyo, JapanPGI47 NonePGI48 Gilead BVBA, Diegem, BelgiumPGI49 Sucampo, Zug, SwitzerlandPGI50 Gilead, Lisbon, PortugalPGI52 Ironwood Pharmaceuticals, Cambridge, MA, USAPGI53 Ministry of Health and Wellfare, Sejong, South KoreaPGI54 Ministry of Health, Labour and Welfare, Tokyo, JapanPGI55 NonePGI56 Gilead Sciences, Foster City, CA, USAPHP1 NonePHP2 NonePHP3 NonePHP4 NonePHP5 SROP-4.2.2.C-11/1/KONV-2012-0005, Well-being in the

Information Society, Budapest, HungaryPHP6 Quintiles Commercial Germany GmbH, Mannheim, Germany;

Healthcare Manufaktur GmbH, Cologne, GermanyPHP8 NonePHP9 NonePHP10 Novartis Farma Italy, Saronno VA, ItalyPHP11 NonePHP12 NonePHP13 NonePHP14 NonePHP15 NonePHP16 NonePHP17 NonePHP18 NonePHP19 NonePHP20 NonePHP21 National Institute for Health Research, London, UKPHP22 NonePHP23 NonePHP24 NonePHP25 Novartis, Dubai, United Arab EmiratesPHP26 Pan Hellenic Union of Pharmaceutical Industry, Athens, GreecePHP27 NonePHP28 European Generics Association, Brussels, BelgiumPHP29 NonePHP30 NonePHP31 NonePHP32 NonePHP33 NonePHP34 NonePHP35 NonePHP37 NonePHP38 NonePHP39 NonePHP40 Medtronic Inc., Istanbul, TurkeyPHP41 Pan Hellenic Union of Pharmaceutical Industry, Athens, GreecePHP42 Qatar National Research Fund, Doha, QatarPHP43 NonePHP44 NonePHP45 NonePHP47 NonePHP49 NonePHP51 NonePHP54 NonePHP55 NonePHP56 NonePHP57 NonePHP58 Boehringer-Ingelheim, Barcelona, SpainPHP59 NonePHP60 German Pharmaceutical Industry Association, Berlin, GermanyPHP61 NonePHP62 NonePHP63 German Federal Ministry of Education and Research (BMBF),

Berlin, GermanyPHP64 NonePHP65 NonePHP66 NonePHP67 NonePHP68 NonePHP69 NonePHP70 NonePHP71 Verband Forschender Arzneimittelhersteller e.V., Berlin, GermanyPHP72 NonePHP73 NonePHP74 NonePHP75 Universidad Nacional de Colombia, Bogotá, ColombiaPHP76 NonePHP77 NonePHP78 NonePHP79 None

Page 6: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A692 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PHP80 AXIS Healthcare Consulting Ltd., Galway, IrelandPHP81 NonePHP82 NonePHP83 NonePHP84 NonePHP86 Roche Products Limited, Welwyn Garden City, UKPHP87 LifeCell Corporation, Bridgewater, NJ, USAPHP88 Boehringer Ingelheim, Bracknell, UKPHP89 Eisai, Inc., Woodcliff Lake, NJ, USAPHP90 NonePHP91 Janssen Cilag, Neuss, GermanyPHP92 NonePHP93 NonePHP94 NonePHP95 NonePHP96 NonePHP97 NonePHP98 NonePHP100 NonePHP101 PAREXEL International, Uxbridge, UKPHP102 NonePHP103 NonePHP104 NonePHP105 NonePHP106 NonePHP107 IHS, London, UKPHP108 NonePHP109 Association of the British Pharmaceutical Industry, London, UKPHP110 NonePHP111 NonePHP112 NonePHP114 Regional Government (Galicia, Spain), Santiago de

Compostela, SpainPHP115 NonePHP116 NonePHP117 NonePHP118 Chang Gung Memorial Hospital, Tao-Yuan, TaiwanPHP119 CareFusion France, Voisins-le-Bretonneux, FrancePHP120 NonePHP121 NonePHP122 Pfi zer Pharma GmbH, Berlin, GermanyPHP123 NonePHP124 NonePHP125 NonePHP126 NonePHP127 NonePHP128 French National Authority of Health (HAS), Paris, FrancePHP129 NonePHP130 NonePHP131 NonePHP132 NonePHP133 SRH Research Foundation, Heidelberg, GermanyPHP134 NonePHP135 NonePHP136 NonePHP137 NonePHP139 Roche Pharma AG, Grenzach-Wyhlen, GermanyPHP140 NonePHP141 NonePHP142 NonePHP143 NonePHP144 NonePHP145 Creativ-Ceutical Ltd., London, UKPHP146 NonePHP147 NonePHP148 Johnson & Johnson Healthcare Systems Inc., Horsham, PA, USAPHP149 Astellas Pharma Europe Ltd., Chertsey, UKPHP150 Novartis Pharma AG, Basel, SwitzerlandPHP151 NonePHP152 Market Access Solutions LLC, Raritan, NJ, USAPHP153 NonePHP154 Medtronic, Istanbul, TurkeyPHP155 NonePHP156 NonePHP157 NonePHP158 NonePHP159 NonePHP160 NonePHP161 NonePHP162 NonePHP163 Novartis Pharma AG, Basel, SwitzerlandPHP164 NonePHP165 NonePHP166 NonePHP167 NonePHP168 IHS, London, UK

REFERENCE CODE

FINANCIAL SUPPORT

PHP169 Great Lakes University of Kisumu, Kisumu, Kenya; KEMRI/CDC, Nairobi, Kenya

PHP170 NonePHP171 NonePHP172 Great Lakes University of Kisumu, Kisumu, KenyaPHP173 NonePHP174 Hellenic Association of Pharmaceutical Companies, Athens,

GreecePHP175 NonePHP176 NonePHP177 Evidera, London, UKPHP178 NonePHP179 St. Luke’s Life Science Institute, Tokyo, JapanPHP180 Great Lakes University of Kisumu, Kisumu, Kenya; KEMRI/CDC,

Kisumu, KenyaPHP181 Great Lakes University of Kisumu, Kisumu, KenyaPHP182 NonePHP183 Novartis Pharma AG, Basel, SwitzerlandPHP184 NonePHP185 European Commission, Bruxelles, BelgiumPHP186 NonePHP187 NonePHP190 NonePHP191 NonePHP192 NonePHP193 NonePHP194 NonePHP195 IHS, London, UKPHP196 NonePHP197 Janssen-Cilag GmbH, Neuss, GermanyPHP198 NonePHP199 NonePHP200 National Institute for Health Research, London, UKPHP201 Universiti Sains Malaysia, Penang, MalaysiaPHP202 NonePHP203 NonePHP204 NonePHP205 NonePHP206 Pharmaceutical Research and Manufacturers of America,

Washington DC, USAPHP207 Pfi zer s.r.o., Prague, Czech RepublicPHP208 NonePHP209 NonePHP210 Roche Pharma AG, Grenzach Wyhlen, GermanyPHP211 NonePHP212 NonePHP214 NonePHP215 NonePHP216 NonePHP217 European Health Technology Institute, Brussels, BelgiumPHP218 NonePHP219 NonePHP220 Pfi zer, Tadworth, UKPHP221 Roche Products Pty Ltd., Dee Why NSW, AustraliaPHP223 NonePHP224 Haute Autorité de Santé, Saint-Denis, FrancePHP225 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,

GermanyPHP226 NonePHP227 NonePHP228 NonePHP229 IHS, London, UKPHP230 NonePHP231 NonePHP232 NonePHP233 IHS, London, UKPHP234 NonePHP235 NonePHP236 NonePHP237 FIOTEC, Brasilia, BrazilPHP238 Janssen-Cilag GmbH, Neuss, GermanyPHP240 Market Access Solutions, London, UKPHP241 NonePHP242 Sorbonne Paris Cité University Network, Paris, France; EHESP

French School of Public Health, Rennes, FrancePHP243 NonePHP244 NonePHP245 FIOTEC, Brasilia, BrazilPHP246 IMS HEALTH GmbH & Co. OHG, Munich, GermanyPHP247 NonePHP248 Top Institute Pharma, Leiden, The NetherlandsPHP249 European Comission, Consumers, Health and Food Executive

Agency, LuxembourgPHP250 NonePHP251 NonePHP252 None

Page 7: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A693

REFERENCE CODE

FINANCIAL SUPPORT

PHP253 NonePHP254 NonePHP255 NonePHP256 NonePHP257 NonePHP258 AstraZeneca, Madrid, SpainPHP259 NonePHP260 NonePHP261 NonePHP263 German Federal Ministry of Economics and Technology, Berlin,

GermanyPHP264 NonePHP265 NonePHP266 NonePHP267 Research-Based Pharmaceutical Companies (Rx&D), Toronto,

ON, CanadaPHP268 NonePHP270 NonePHP271 NonePHP272 NonePHP273 GlaxoSmithKline, Wavre, Belgium; Deloitte, Diegem, BelgiumPHP274 Pfi zer UK Ltd., Walton Oaks, UKPHP275 Sanofi Pasteur MSD, Lyon, FrancePHP277 NonePHP278 NonePHP279 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPHP280 NonePHP281 NonePHP282 Quintiles Consulting, Hawthorne, NY, USAPHP283 NonePHP284 NonePHP285 NonePHP286 NonePHP287 NonePHP288 NonePHP289 NonePHP290 NonePHP291 NonePHP295 NonePHP296 NonePHP297 Medtronic, Istanbul, TurkeyPIH1 NonePIH2 NonePIH3 Novartis Pharma, Nuremberg, GermanyPIH4 Astellas, Leiden, The NetherlandsPIH5 NonePIH6 National Institute for Health Research, London, UKPIH7 NonePIH8 Agency for Integrated Care, Singapore, SingaporePIH10 NonePIH11 NonePIH13 NonePIH14 FP7-HEALTH, EU, IrelandPIH15 State of Vermont Green Mountain Care Board,

Montpelier, VT, USAPIH16 Nestle Health Science, Barcelona, SpainPIH17 NonePIH18 NonePIH19 NonePIH20 GlaxoSmithKline, Warsaw, PolandPIH21 NonePIH22 Abbott, Moscow, RussiaPIH23 Merck Sharp and Dohme, Hoddesdon, UKPIH24 Ferring Pharmaceuticals Poland Sp. z o. o., Warsaw, PolandPIH25 SPMSD, Lyon, FrancePIH26 AMS, Madrid, SpainPIH27 NonePIH28 Merck & Co., Inc., West Point, PA, USAPIH29 GlaxoSmithKline S.R.L., Bucharest, RomaniaPIH30 NonePIH31 NonePIH32 Ministry of Health and Social Protection, Bogota, Colombia;

Administrative Department of Science, Technology and Innovation, Colciencias, Bogota, Colombia

PIH33 Gedeon Richter Romania SA, Corunca, RomaniaPIH34 HRA Pharma, Paris, FrancePIH35 Besins, São Paulo, BrazilPIH36 NonePIH37 NonePIH38 Medical University Astana, Astana, KazakhstanPIH39 Federal Ministry of Education and Research, Berlin, GermanyPIH40 NonePIH41 Pierre Fabre Italia S.p.a., Milan, ItalyPIH42 Sanofi Pasteur, ROME, ItalyPIH43 Consejo General de Colegios Ofi ciales de Farmaceuticos, Madrid,

Spain; Laboratorios Cinfa, Navarra, Spain

REFERENCE CODE

FINANCIAL SUPPORT

PIH44 NonePIH45 NonePIH46 NonePIH47 Covance, San Diego, CA, USAPIH48 NonePIH49 NonePIH50 NonePIH51 Health Research Board, Dublin, IrelandPIH52 National Institute of Health Research, Southampton, UKPIH53 Solvay Pharma, Hannover, GermanyPIH54 Creativ-Ceutical, London, UKPIH55 NonePIH56 NonePIH57 NonePIH58 NonePIH59 NonePIH60 NonePIH61 NonePIH62 NonePIH63 Qatar University, Doha, QatarPIH64 NonePIH65 NonePIH66 NonePIH67 NonePIH68 NonePIH69 KJT Group, Honeoye Falls, NY, USAPIH70 NonePIH71 EuroQol Foundation, Rotterdam, The Netherlands; Fondo

Nacional de Recursos, Montevideo, UruguayPIH72 NonePIH73 NonePIH74 Mapi, Lyon, FrancePIH75 Bayer Yakuhin, Ltd., Osaka, JapanPIH76 Exco InTouch, Nottingham, UKPIH77 Novartis Pharma AG, Basel, SwitzerlandPIH78 NonePIH79 NonePIH80 NonePIH81 Nestle Health Science, Barcelona, SpainPIH82 NonePIH83 National Health and Medical Research Council, ACT, AustraliaPIH84 Eli Lilly and Company, Indianapolis, IN, USAPIH85 Anvisa, Brasilia, BrazilPIH86 ANVISA, Brasília, BrazilPIH87 Department of Health and Social Action (DSAS) of the canton of

Vaud, Canton of Vaud, SwitzerlandPIH88 NonePIH89 EMD Serono, Inc., Rockland, MA, USAPIH90 NonePIH91 NonePIH92 NonePIH93 NonePIH94 Pfi zer, S.L.U., Madrid, Spain; Spanish Association for the Study

of Menopause, Madrid, Spain; Universidad Autónoma de Madrid, Madrid, Spain

PIH95 Taipei City Department of Health, Taipei, TaiwanPIH96 GlaxoSmithKline Vaccines, Wavre, BelgiumPIH97 Covance Market Access Services, Gaithersburg, MD, USAPIH98 NonePIH99 Eli Lilly and Company, Basingstoke, UKPIN1 Janssen, Beerse, BelgiumPIN2 Cubist Pharmaceuticals, Lexington, MA, USAPIN3 NonePIN4 The Medicines Company, Parsippany, NJ, USAPIN5 Sanofi Pasteur, Lyon, FrancePIN6 NonePIN7 NonePIN8 Astellas Pharma Kft., Budapest, HungaryPIN9 Janssen EMEA, Beerse, BelgiumPIN11 NonePIN12 NonePIN13 THRiVE, KAMPALA, UgandaPIN14 Bristol Myers Squibb, New Jersey, NJ, USAPIN15 GalxoSmithKline Biologicals SA, Rixensart, BelgiumPIN16 NonePIN17 NonePIN18 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPIN19 NonePIN20 Cubist Pharmaceuticals, Lexington, MA, USAPIN21 Johnson & Johnson Medical, Madrid, SpainPIN22 NonePIN23 Pfi zer Brasil, São Paulo, BrazilPIN24 NonePIN25 Astellas Pharma a/s, Kastrup, DenmarkPIN26 Sanofi Pasteur MSD, Lyon, FrancePIN27 Pfi zer, Inc., São Paulo, Brazil

Page 8: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A694 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PIN28 Sanofi , Sao Paulo, BrazilPIN29 NonePIN30 NonePIN31 Ministry of Health, Labour and Welfare, Tokyo, JapanPIN32 NonePIN33 Pfi zer Deutschland GmbH, Berlin, GermanyPIN34 Delta Medical Promotions, Moscow, RussiaPIN35 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPIN36 Johnson and Johnson Sıhhi Malzeme San. ve Tic. Ltd.

Sti., Istanbul, TurkeyPIN37 Johnson and Johnson Sıhhi Malzeme San. ve Tic. Ltd.

Sti, Istanbul, TurkeyPIN38 Pfi zer Inc., Beijing, ChinaPIN39 Astellas Pharma a/s, Kastrup, DenmarkPIN40 Robert Koch Institute, Berlin, GermanyPIN41 NonePIN42 Pfi zer, New York, NY, USAPIN43 NonePIN44 AstraZeneca GmbH, Wedel, GermanyPIN45 NonePIN46 NonePIN47 NonePIN48 Sanofi Pasteur MSD, Lyon, FrancePIN49 NonePIN50 NonePIN51 NonePIN52 Roche Diagnostics S.p.A, Milan, ItalyPIN53 GlaxoSmithKline S.A., Madrid, Spain; GlaxoSmithKline – Produtos

Farmacêuticos, Lda., Lisbon, PortugalPIN54 GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi

izdelki, Ljubljana, SloveniaPIN55 Gilead Sciences The Netherlands, Amsterdam, The NetherlandsPIN56 GlaxoSmithKline Biologicals SA, Wavre, BelgiumPIN57 Astellas Pharma a/s, Kastrup, DenmarkPIN58 Pfi zer Inc., Collegeville, PA, USAPIN59 Sanofi Pasteur, Rome, ItalyPIN60 Astellas Pharma, MADRID, SpainPIN61 AstraZeneca, Rueil-Malmaison, FrancePIN62 Janssen-Cilag, Neuss, GermanyPIN63 NonePIN64 Astellas Pharma, Budapest, HungaryPIN65 Merck Sharp & Dohme, Athens, GreecePIN66 Gilead Sciences, Foster City, CA, USAPIN67 Gilead Sciences, Foster City, CA, USAPIN68 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPIN69 GlaxoSmithKline Biologicals SA, Rixensart, BelgiumPIN70 Sanofi Pasteur MSD, Madrid, SpainPIN71 NonePIN72 GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi

izdelki, Ljubljana, Slovenia, Ljubljana, SloveniaPIN73 Gilead Sciences The Netherlands, Amsterdam, The NetherlandsPIN74 GlaxoSmithKline, Wavre, BelgiumPIN75 BD, Shanghai, ChinaPIN76 Merck Sharp & Dohme, Corp., Whitehouse Station, NJ, USAPIN77 GILEAD, ISTANBUL, TurkeyPIN78 NonePIN79 NonePIN80 GILEAD, ISTANBUL, TurkeyPIN81 NonePIN82 NonePIN83 NonePIN84 GSK, Marly Le Roi, FrancePIN85 ViiV Healthcare, Marly le Roi, FrancePIN86 Janssen EMEA, Beerse, BelgiumPIN87 Sanofi Pasteur, Lyon, FrancePIN88 ViiV Healthcare, Brentford, Middlesex, UKPIN89 University Malaya, Kuala Lumpur, MalaysiaPIN90 Hutman Diagnostics AG, Basel, SwitzerlandPIN91 SPMSD, Lyon, FrancePIN92 Janssen Cilag, Neuss, GermanyPIN93 Truven Health Analytics, Bethesda, MD, USAPIN94 NonePIN95 NonePIN96 Janssen Pharmaceutica NV, Beerse, BelgiumPIN97 NonePIN98 NonePIN99 NonePIN100 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPIN101 NonePIN102 Janssen Research and Development, Beerse, BelgiumPIN103 NonePIN104 NonePIN105 NonePIN106 Bristol-Myers Squibb Pharmaceuticals Ltd., New York, NY, USAPIN107 NonePIN108 Pfi zer, New York, NY, USA

REFERENCE CODE

FINANCIAL SUPPORT

PIN109 NHS R&D Health Technology Assessment (HTA) Programme, Southampton, UK

PIN111 NonePIN112 Decision Resources Group, Burlington, MA, USAPIN113 GlaxoSmithKline Biologicals, Rixensart, BelgiumPIN114 Merck and Co., Inc., West Point, PA, USAPIN115 Health Research Board, Dublin, IrelandPIN116 AstraZeneca UK Ltd., Luton, UKPIN117 Federal Ministry of Education and Research (BMBF), Berlin,

Germany; Ministry of Education, Science and Culture of the state Mecklenburg-Western Pomerania, Schwerin, Germany

PIN118 NonePIN119 NonePIN120 NonePIN121 NonePIN122 NonePIN123 BMGF, Seattle, DC, USAPIN124 NonePIN125 NonePMH1 Lundbeck Italia S.p.A., Milano, ItalyPMH2 Ministry of Health and Welfare, Seoul, South KoreaPMH3 MyCognition, London, UKPMH4 Innovatiefonds Zorgverzekeraars, Zeist, The NetherlandsPMH5 Shire Development LLC, Wayne, PA, USAPMH6 Cheplapharm Arzneimittel GmbH, Greifswald - Insel Riems,

GermanyPMH7 Eli Lilly and Company Ltd., Indianapolis, IN, USAPMH8 NIHR, Southampton, UK; MRC ConDuCT Hub for Trials

Methodology Research, Swindon, UKPMH9 National Institute for Health Research, Southampton, UKPMH10 Eli Lilly and Company Ltd., Indianapolis, IN, USAPMH11 NonePMH12 Ministry of Health, Labour and Welfare, Japan, Tokyo, JapanPMH13 NonePMH14 Janssen-Cilag GmbH, Neuss, GermanyPMH15 Roche Farma, Madrid, SpainPMH16 Janssen Global Services, New Jersey, NJ, USAPMH17 Reckitt Benckiser, Richmond, VA, USAPMH18 Janssen, Sao Paulo, BrazilPMH19 Janssen Inc., Toronto, ON, CanadaPMH20 Janssen-Cilag AG, Zug, SwitzerlandPMH21 Mundipharma International Limited, Cambridge, UKPMH22 Janssen-Cilag GmbH, Neuss, GermanyPMH23 Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, ChinaPMH24 Eli Lilly, Windlesham, UKPMH25 Lundbeck, Issy-les-Moulineaux, FrancePMH26 NIHR HTA programme, Southampton, UKPMH27 Lundbeck Hellas SA, Athens, GreecePMH28 Eli Lilly and Company, Windlesham, UKPMH29 Janssen-Cilag Gmbh, Neuss, GermanyPMH30 National Institute for Health Research HTA Programme,

Southampton, UK; University of Sheffi eld, Sheffi eld, UKPMH31 National Institute for Health Research, Southampton, UKPMH32 The National Institute for Health Research - Health Technology

Assessment HTA Programme, London, UKPMH33 Janssen-Cilag s.r.o., Prague, Czech RepublicPMH34 Lundbeck SAS, Issy les Moulineaux, FrancePMH35 Janssen Cilag, Issy-Les-Moulineaux, FrancePMH36 NonePMH37 Eli Lilly, Windlesham, UKPMH38 Ferrer, Barcelona, SpainPMH39 NonePMH40 NonePMH41 NonePMH42 Janssen-Cilag NV, Beerse, BelgiumPMH43 Janssen-Cilag GmbH, Neuss, GermanyPMH44 Bristol City Council, Bristol, UKPMH45 Shire Development LLC, Wayne, PA, USAPMH46 NonePMH47 NonePMH48 NonePMH49 Lundbeck S.A.S., Issy-les-Moulineaux Cedex, UKPMH50 Lundbeck S.A.S., Issy-les-Moulineaux Cedex, FrancePMH51 Janssen-Cilag BV, Tilburg, The NetherlandsPMH52 Lundbeck SAS, Issy-les-Moulineaux, FrancePMH53 NonePMH54 NonePMH55 Health Services Executive, Cork, IrelandPMH56 Pfi zer Japan Inc., Tokyo, JapanPMH57 Ferrer, Barcelona, SpainPMH58 Reckitt Benckiser, Richmond, VA, USAPMH59 NonePMH60 Shire Development LLC, Wayne, PA, USAPMH61 NonePMH62 NonePMH63 None

Page 9: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A695

REFERENCE CODE

FINANCIAL SUPPORT

PMH64 NonePMH65 Pfi zer, S.L.U., Madrid, SpainPMH66 The research is funded by EU-ICT FP7-eHM, project-ID-287509,

Brussels, GermanyPMH67 Lundbeck SAS, Issy-les-Moulineaux, FrancePMH69 NonePMH70 KJT Group, Inc., Honeyoe Falls, NY, USAPMH71 Lundbeck SAS, Paris, FrancePMH72 NonePMH73 NonePMH74 NonePMS1 Celgene Corporation, Warren, NJ, USAPMS2 Celgene Corporation, Warren, NJ, USAPMS3 Janssen Pharmaceutica N.V., Beerse, BelgiumPMS4 NonePMS5 NonePMS6 Bristol Myers Squibb, Rome, ItalyPMS7 National Evidence-based Healthcare Collaborating Agency, Seoul,

South KoreaPMS8 Hanwha Chemical, Seoul, South KoreaPMS9 NonePMS10 Roche, Basel, SwitzerlandPMS11 National Science Council, Taipei, Taiwan; Pfi zer Taiwan, Taipei,

TaiwanPMS12 Bioventus LLC, Durham, NC, USAPMS13 Janssen-Cilag GmbH, Neuss, GermanyPMS14 Janssen Pharmaceutical, Athens, GreecePMS15 UCB Pharma, Brussels, BelgiumPMS16 NonePMS17 Medtronic LLC, Moscow, RussiaPMS18 Medtronic, Tolochenaz, SwitzerlandPMS19 Celgene Corporation, Warren, NJ, USAPMS20 Pfi zer, Lisbon, PortugalPMS21 Medtronic International Trading Sàrl, Tolochenaz, SwitzerlandPMS22 MSD B.V., Haarlem, The NetherlandsPMS23 UCB Pharma, Brussels, BelgiumPMS24 NonePMS25 UCB Pharma, Brussels, BelgiumPMS26 IPSEN Pharma, Boulogne-Billancourt, FrancePMS27 AMGEN Brazil, Sao Paulo, BrazilPMS28 NonePMS29 NonePMS30 Novartis Pharmaceuticals UK Limited, Camberley, UKPMS31 Novartis Pharmaceuticals UK Limited, Camberley, UKPMS32 NonePMS33 Johnson and Johnson, New Brunswick, NJ, USAPMS34 NonePMS35 Bristol-Myers Squibb, Princeton, NJ, USAPMS36 NonePMS37 NonePMS38 UCB Pharma S.A, Brussels, BelgiumPMS39 NonePMS40 Pfi zer, S.L.U., Madrid, SpainPMS41 NIHR HTA, Southamptom, UKPMS42 Telecom Italia, Rome, ItalyPMS43 NonePMS44 Intrinsic Therapeutics, Inc., Woburn, MA, USAPMS45 Roche, Moscow, RussiaPMS46 Pfi zer, Lisbon, PortugalPMS47 Savient Pharma Ireland Limited, Dublin, IrelandPMS48 National Evidence-based Healthcare Collaborating Agency, Seoul,

South KoreaPMS49 Stryker, PUSIGNAN, FrancePMS50 Ministry of Education, Culture, Sports, Science and Technology,

Grant-in-Aid for Scientifi c Research (KAKENHI), Tokyo, JapanPMS51 NonePMS52 NIHR RFPB grant, Twickenham, UKPMS53 NonePMS54 UCB Pharma, Brussels, BelgiumPMS55 Servier, Petaling Jaya, MalaysiaPMS56 Roche Products Limited, Welwyn Garden City, UKPMS57 NonePMS58 Yrjö Jahnsson Foundation, Helsinki, FinlandPMS59 Bristol-Myers Squibb, Princeton, NJ, USAPMS60 NonePMS61 NonePMS62 Roche, Monza, ItalyPMS63 Amgen Inc., Thousand Oaks, CA, USAPMS64 Merck & Co., Inc., Whitehouse Station, NJ, USAPMS65 Merck & Co., Inc., Whitehouse Station, NJ, USAPMS66 NonePMS67 National Institute of Arthritis and Musculoskeletal and Skin

Diseases, Houston, TX, USAPMS68 Merck & Co., Inc., Whitehouse Station, NJ, USAPMS69 NonePMS70 Janssen-Cilag Ltd., High Wycombe, UK

REFERENCE CODE

FINANCIAL SUPPORT

PMS71 Pfi zer Deutschland GmbH, Berlin, GermanyPMS72 Amgen, Zug, SwitzerlandPMS73 UCB Pharma, Brussels, BelgiumPMS74 Merck Sharpe & Dohme, Whitehouse Station, NJ, USAPMS75 Janssen Global Services, Titusville, NJ, USA; Janssen R&D,

Raritan, NJ, USAPMS76 UCB Pharma, Brussels, BelgiumPMS77 Janssen Global Services, Titusville, NJ, USA; Janssen Research

and Development, Raritan, NJ, USAPMS78 AbbVie, Stockholm, SwedenPMS79 MSD, Athens, GreecePMS80 NonePMS81 Pfi zer Deutschland GmbH, Berlin, GermanyPMS82 NonePMS83 UCB Pharma, Brussels, BelgiumPMS84 UCB Pharma, Brussels, BelgiumPMS85 NonePMS86 Double Helix Consulting, London, UKPMS87 NonePMS88 ICON Plc., London, UKPMS89 NonePMS90 Plan de Calidad para el Sistema Nacional de Salud, Madrid, SpainPMS91 NonePMS92 Amgen Bulgaria, Sofi a, BulgariaPMS93 Amgen Switzerland AG, Zug, SwitzerlandPMS94 Canadian Institute for Health Research (CIHR), Ottawa, ON,

Canada; Canadian Arthritis Society, Toronto, ON, CanadaPMS95 Merck, North Wales, PA, USAPMS96 AstraZeneca Canada Inc., Mississauga, ON, CanadaPMS97 Pfi zer Pharmaceuticals Korea Ltd., Seoul, South KoreaPND1 EMD Serono, Rockland, MA, USAPND2 GSK, Brentford, UKPND3 Abbvie, Madrid, SpainPND4 Genzyme, A Sanofi Company, Cambridge, MA, USAPND5 NonePND6 Ministry of Health and Welfare, Seoul, South KoreaPND7 NonePND8 Biogen Idec, Cambridge, MA, USAPND9 Medtronic, Minneapolis, MN, USAPND10 Genzyme, a Sanofi company, Cambridge, MA, USAPND11 NonePND12 Biogen Idec, Cambridge, MA, USAPND13 EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt,

Germany, Rockland, MA, USAPND14 NonePND15 Biogen Idec, Cambridge, MA, USAPND16 Orion Corporation, Espoo, FinlandPND17 Medtronic, Minneapolis, MN, USAPND18 Novartis, Milan, ItalyPND19 Teva Pharmaceuticals Europe B.V., Amsterdam, The NetherlandsPND20 Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo,

PortugalPND21 Medtronic, Tolochenaz, SwitzerlandPND22 Teva Pharma, Madrid, SpainPND23 Biogen Idec, Cambridge, MA, USAPND24 NRF, Pretoria, South AfricaPND25 UCB Pharma, Brussels, BelgiumPND26 Ipsen Operations Russia, Moscow, RussiaPND27 Medtronic International, Tolochenaz, SwitzerlandPND28 NonePND29 Abbvie, Madrid, SpainPND30 NonePND31 NonePND32 NonePND33 Merck SA, Alges, PortugalPND34 Medtronic Ibérica, S.A., Madrid, SpainPND35 Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USAPND36 NonePND37 Biogen Idec Slovak Republic Ltd., Bratislava, Slovak RepublicPND38 NonePND39 Biogen Idec s.r.o., Prague, Czech RepublicPND40 EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt,

Germany, Rockland, MA, USAPND41 EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt,

Germany, Rockland, MA, USAPND42 UCB Pharma, Athens, GreecePND43 Merck SA, Alges, PortugalPND44 Boston Scientifi c, Milan, ItalyPND45 EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt,

Germany, Rockland, MA, USAPND46 French Ministry of Health, Paris, FrancePND47 Biogen Idec, Weston, MA, USAPND48 NonePND49 Novartis Pharmaceuticals UK Ltd., Camberley, UKPND50 Alvogen Pharma doo Serbia, Belgrade, Serbia and MontenegroPND51 None

Page 10: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A696 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PND52 Funding for analysis was provided by Genzyme, a Sanofi company, Helsinki, Finland

PND53 Medtronic Ibérica, S.A., Madrid, SpainPND54 NonePND55 Biogen Idec, Ismaning, GermanyPND56 EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt,

Germany, Rockland, MA, USAPND57 Funding for analysis was provided by Genzyme, a Sanofi

company, Helsinki, FinlandPND58 Novartis Pharma AG, Basel, SwitzerlandPND59 Novartis Pharma AG, Basel, SwitzerlandPND60 NonePND61 NonePND62 Biogen Idec, Cambridge, MA, USAPND63 Eisai Inc., Woodcliff Lake, NJ, USAPND64 Biogen Idec, Cambridge, MA, USAPND65 Eisai, Inc., Woodcliff Lake, NJ, USAPND66 Novartis Farmacéutica, S.A., Barcelona, SpainPND67 Eli Lilly and Company, Indianapolis, IN, USAPND68 Lilly Deutschland GmbH, Bad Homburg, GermanyPND69 Eisai, Inc., Woodcliff Lake, NJ, USAPND70 Biogen Idec, Cambridge, MA, USAPND71 Novartis Farmacéutica, Barcelona, SpainPND72 Biogen Idec, Ismaning, GermanyPND73 Genzyme, a Sanofi company, Cambridge, MA, USAPND74 UCB Pharma, Brussels, BelgiumPND75 NonePND76 NonePND77 NonePND78 NonePND79 NonePND80 NonePRM1 Eli Lilly and Company Ltd., Indianapolis, IN, USAPRM2 NonePRM3 NIHR, Leeds, UKPRM4 Patient-Centered Outcomes Research Institute (PCORI),

Washington, DC, USAPRM5 ICON Clinical Research UK, Eastleigh, UKPRM6 NonePRM7 NonePRM8 NonePRM9 NonePRM10 Mapi, Boston, MA, USAPRM11 ICON PLC, Oxford, UKPRM12 Pfi zer Ltd., Walton Oaks, UKPRM13 Thai Traditional Medical Knowledge Fund, Department for

Development of Thai Traditional and Alternative Medicine, Ministry of Public Health, Bangkok, Thailand

PRM14 Mundipharma International Limited, Cambridge, UKPRM15 Janssen, High Wycombe, UKPRM16 AstraZeneca plc, Molndal, SwedenPRM17 NonePRM18 Janssen Pharmaceutica NV, beerse, BelgiumPRM19 NonePRM20 NonePRM21 IRD, Marseille, FrancePRM22 NonePRM23 NonePRM24 2Actelion Pharmaceuticals US, Inc., San Francisco, CA, USAPRM25 NonePRM26 Medical Research Council, London, UK; Cancer Research UK,

London, UK; UK Department of Health, London, UKPRM27 Medical Research Council (Network of Hubs for Trials

Methodology Research Network Grant ref: R35), London, UK; The National Institute for Health Research (NIHR) (Programme Grant for Applied Research (RP-PG-0407-10070))., London, UK

PRM28 Novartis Pharmaceuticals UK Ltd., Camberley, UKPRM29 NonePRM30 AbbVie, Chicago, IL, USAPRM31 NonePRM32 NonePRM33 NonePRM34 NonePRM35 GILEAD, London, UKPRM36 NonePRM37 Bristol Myers Squibb, Uxbridge, UKPRM38 Universidad Nacional de Colombia, Bogota, ColombiaPRM39 NonePRM40 NonePRM41 NonePRM42 NonePRM43 NonePRM44 Eli Lilly, Indianapolis, IN, USAPRM45 NonePRM46 NonePRM47 Novartis Pharma AG, Basel, SwitzerlandPRM48 None

REFERENCE CODE

FINANCIAL SUPPORT

PRM50 Center for translational and molecular medicine, Eindhoven, The Netherlands

PRM51 Federal Ministry of Health, Berlin, GermanyPRM52 NonePRM53 ALLEGRIA onlus, Milano, ItalyPRM54 Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USAPRM55 Health Research Board, Dublin, IrelandPRM56 Truven Health Analytics, Ann Arbor, MI, USAPRM57 Sanofi -Aventis Hungaria, Budapest, HungaryPRM58 Mapi Research Trust, Lyon, FrancePRM59 Mapi Research Trust, Lyon, FrancePRM60 NonePRM61 IMS Health, London, UK; AstraZeneca, Manchester, UKPRM62 PPD, Wilmington, NC, USAPRM63 NonePRM64 NonePRM65 ZonMW, The Hague, The NetherlandsPRM66 GSK Biologicals SA, Wavre, BelgiumPRM67 NonePRM68 HealthCore, Wilmington, DE, USAPRM69 NonePRM70 Truven Health Analytics, Bethesda, MD, USAPRM71 NonePRM72 NonePRM73 NonePRM74 National Institute for Health Research, London, UKPRM75 NonePRM76 NonePRM77 NonePRM78 NonePRM79 The Netherlands Organization for Health Research and

Development (ZonMW), The Hague, The NetherlandsPRM80 Bristol Myers Squibb, Uxbridge, UKPRM81 NonePRM82 NonePRM83 Eisai, Inc., Woodcliff Lake, NJ, USAPRM84 Boehringer Ingelheim International Gmbh, Ingelheim am Rhein,

Germany; Boehringer Ingelheim The The Netherlands, Alkmaar, The Netherlands; GlaxoSmithKline, Middlesex, UK; Novartis, Basel, Switzerland; Takeda Pharmaceuticals, Glattpark-Opfi kon, Switzerland

PRM85 Novartis Pharma AG, Basel, SwitzerlandPRM86 Janssen-Cilag A/S, Birkerød, DenmarkPRM87 NonePRM88 Amgen, Zug, SwitzerlandPRM89 NonePRM90 Novartis Pharmaceuticals UK Limited, Frimley, UKPRM91 Supported by the COMET Center ONCOTYROL, which is funded

by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT), Innsbruck, Austria

PRM92 Mundipharma International Limited, Cambridge, UKPRM93 Genome Quebec, Montreal, QC, CanadaPRM94 Oncotyrol, Innsbruck, AustriaPRM95 NonePRM96 Innovative Medicine Initiative Joint Undertaking, Bern, SwitzerlandPRM97 3M Deutschland GmbH, Neuss, GermanyPRM98 NonePRM99 NonePRM100 GSK, Research Triangle Park, NC, USAPRM101 NonePRM102 NonePRM103 Genome Quebec, Montreal, QC, CanadaPRM104 GlaxoSmithKline, Wavre, BelgiumPRM105 CTTM, Eindhoven, The NetherlandsPRM106 Novartis Pharma AG, Basel, SwitzerlandPRM107 Boehringer Ingelheim, Ingelheim am Rhein, GermanyPRM108 ViroPharma, Maidenhead, UKPRM109 Austrian Research Promotion Agency (FFG), Vienna, AustriaPRM110 GlaxoSmithKline, Bilthoven, The NetherlandsPRM111 Sanofi , Guildford, UKPRM112 NonePRM113 Navigant Consulting, London, UKPRM114 National Institute of Health Research (NIHR), London, UKPRM115 GlaxoSmithKline, Collegeville, PA, USAPRM116 Decision Resources, LLC, Burlington, MA, USAPRM117 3M Deutschland GmbH, Neuss, GermanyPRM118 Otsuka Pharmaceutical Europe Ltd., Wexham, UKPRM119 Decision Resources Group, Burlington, MA, USAPRM120 F. Hofmann – La Roche AG, Basel, SwitzerlandPRM121 RTI-HS, Manchester, UKPRM123 Evidera, San Francisco, CA, USAPRM124 Costello Medical Consulting Ltd., Cambirdge, UKPRM125 AstraZeneca, Gaithersburg, MD, USAPRM126 Les Entreprises du Médicament (LEEM), Paris, FrancePRM127 NonePRM128 None

Page 11: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A697

REFERENCE CODE

FINANCIAL SUPPORT

PRM129 RTI Health Solutions, Research Triangle Park, NC, USAPRM130 NonePRM131 Pharmerit, Rotterdam, The NetherlandsPRM132 UICC, Geneva, SwitzerlandPRM133 Agility Global Health Solutions (AGHS), Centurion, South AfricaPRM134 NonePRM135 NonePRM136 NonePRM137 Basilea Pharmaceuticals, München, Germany; Glaxo Smith Kline,

München, GermanyPRM138 Medivation, Inc., San Francisco, CA, USA; Astellas Pharma Global

Development, Inc., Northbrook, IL, USAPRM139 RIVM, Bilthoven, The NetherlandsPRM140 Ministry of Health, Malaysia, MalaysiaPRM141 NonePRM142 NonePRM143 DePuy Orthopaedics, Inc., Warsaw, IN, USAPRM144 UCB Pharma, Brussels, BelgiumPRM145 Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPRM146 Regeneron Pharmaceuticals, Tarrytown, NY, USAPRM147 Ontario Institute for Cancer Research and Cancer Care Ontario,

Toronto, ON, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada

PRM148 Bristol Myers Squibb, Uxbridge, UKPRM149 RTI-Health Solutions, Research Triangle Park, NC, USAPRM150 NonePRM151 UCB Pharma, Brussels, BelgiumPRM152 Amgen (Europe) GmbH, Zug, SwitzerlandPRM153 EuroQol Group, Rotterdam, The NetherlandsPRM154 EuroQol Group Foundation, Rotterdam, The NetherlandsPRM155 AbbVie, Campoverde di Aprilia (LT), ItalyPRM156 RTI-HS, RTP, NC, USAPRM157 The EuroQol Group, Rotterdam, The NetherlandsPRM158 Mapi, Lyon, FrancePRM159 AstraZeneca Ltd., Macclesfi eld, EnglandPRM160 NonePRM161 Pfi zer Ltd., Tadworth, UKPRM162 EuroQol Group, Rotterdam, The NetherlandsPRM163 NonePRM164 NonePRM165 NonePRM166 NonePRM167 NonePRM168 NonePRM169 Abacus International, Bicester, UKPRM170 NonePRM171 NonePRM172 NonePRM173 NonePRM174 NonePRM175 NonePRM176 NonePRM177 NonePRM178 NonePRM179 Bayer Yakuhin Ltd., Tokyo, JapanPRM180 PAR Inc., Lutz, FL, USAPRM181 Lumena, San Diego, CA, USAPRM182 Nestle Health Science, Barcelona, SpainPRM183 German Federal Ministry of Education and Research, Berlin,

GermanyPRM184 Eisai Inc., Woodcliff Lake, NJ, USAPRM186 NonePRM187 NonePRM188 IMI, Brussels, BelgiumPRM189 Creativ-ceutical, London, UKPRM190 Abacus International, Bicester, UKPRM191 Creativ-ceutical, London, UKPRM192 GlaxoSmithKline, Philadelphia, PA, USAPRM193 Lunbeck, Issy-les-Moulineaux, FrancePRM194 F. Hoffmann-La Roche, Basel, SwitzerlandPRM195 Leicester University, Leicester, UKPRM196 NonePRM197 NonePRM198 Eli Lilly Regional Operations Ges.m.b.H., Vienna, AustriaPRM199 NonePRM200 Agence Nationale de Sécurité des Médicaments, Sain-Denis,

FrancePRM201 NonePRM202 NIHR, Leeds, UKPRM203 Takeda Pharmaceuticals International GmbH, Zurich, SwitzerlandPRM204 Health Research Board, Dublin, IrelandPRM205 NonePRM206 Shire Development LLC, Wayne, PA, USAPRM207 NonePRM208 Ministry of Health of the Czech Republic, Prague, Czech RepublicPRM210 NonePRM211 EveryLife Foundation for Rare Diseases, Novato, CA, USA

REFERENCE CODE

FINANCIAL SUPPORT

PRM212 NonePRM214 Celgene Corporation, Summit, NJ, USAPRM215 NonePRM216 NonePRM217 NonePRM218 NonePRM219 GlaxoSmithKline, Uxbridge, UKPRM220 NonePRM221 Almirall, Uxbridge, UKPRM222 NonePRM223 GlaxoSmithKline, Wavre, BelgiumPRM224 NonePRM225 NonePRM226 NonePRM227 MAPI, Lyon, FrancePRM228 NonePRM229 The Netherlands Organization for Scientifi c Research, The Hague,

The NetherlandsPRM230 Evidera, Bethesda, MD, USAPRM231 NonePRM232 NonePRM234 NonePRM235 National Institute for Health Research, London, UKPRM236 NonePRM237 NonePRM238 NonePRM239 Bridge Medical, London, UKPRM240 NIHR Evaluation, Trials and Studies, Southampton, UKPRM241 Eli Lilly Regional Operations GmbH, Vienna, AustriaPRM242 NonePRM243 NonePRM244 Eli Lilly Regional Operations GmbH, Vienna, AustriaPRM245 Novo Nordisk, Bagsværd, DenmarkPRM246 NonePRM247 IMI, Brussels, BelgiumPRM248 Quintiles, Reading, UKPRM249 Santen, Inc., Emeryville, CA, USAPRM250 Novartis, Moscow, RussiaPRM251 Eli Lilly Regional Operations GmbH, Vienna, AustriaPRM252 NonePRM253 Onyx Pharmaceuticals, Inc., San Francisco, CA, USAPRM254 Amaris, London, UKPRM255 Axonal, Paris, FrancePRM256 MoH Brazil, Brasilia, BrazilPRS1 Thermo Fisher Scientifi c, Uppsala, SwedenPRS2 MSD France, Courbevoie, FrancePRS3 Novartis, Istanbul, TurkeyPRS4 Basilea Pharmaceutica Ltd., Basel, SwitzerlandPRS5 GlaxoSmithKline Inc., RTP, NC, USAPRS6 Novartis, Basel, SwitzerlandPRS7 Novartis, East Hannover, NJ, USAPRS8 NonePRS9 NonePRS10 NonePRS11 Takeda Development Centre Europe Ltd., London, UKPRS12 Takeda Development Centre Europe, London, UKPRS13 NA, CA, USAPRS14 Takeda Pharmaceuticals International, London, UKPRS15 NonePRS16 NonePRS17 GSK, Uxbridge, UKPRS18 GSK, Uxbridge, UKPRS19 Teva Pharmaceuticals Europe B.V, Amsterdam, The NetherlandsPRS20 Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo,

PortugalPRS21 Boehringer Ingelheim, Bracknell, UKPRS22 Pfi zer, Inc., São Paulo, BrazilPRS23 GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi

izdelki, Ljubljana, Slovenia, Ljubljana, SloveniaPRS24 GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi

izdelki, Ljubljana, Slovenia, Ljubljana, SloveniaPRS25 ResMed Germany Inc., Martinsried, GermanyPRS26 Biogen Idec, Cambridge, MA, USAPRS27 NonePRS28 Glaxosmithkline, Ýstanbul, TurkeyPRS29 Actelion Pharmaceuticals Ltd., Allschwil, SwitzerlandPRS30 Pfi zer, New York, NY, USAPRS31 Novartis Korea, Seoul, South KoreaPRS32 Glaxosmithkline, Ýstanbul, TurkeyPRS33 NonePRS34 Ministry for Health, Welfare & Family Affairs, Seoul, South KoreaPRS35 NonePRS36 NonePRS37 IMU, KL, MalaysiaPRS38 IMU, KL, MalaysiaPRS39 NonePRS40 None

Page 12: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

A698 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9

REFERENCE CODE

FINANCIAL SUPPORT

PRS41 GlaxoSmithKline S.R.L., Bucharest, RomaniaPRS42 Stichting Achmea Gezondheidszorg, Zeist, The Netherlands;

The Netherlands Organisation for Health Research and Development (Zon-MW), Den Haag, The Netherlands

PRS43 Janssen Pharmaceutica NV, Beerse, BelgiumPRS44 GlaxoSmithKline Inc., RTP, NC, USAPRS45 GlaxoSmithKline, Uxbridge, UKPRS46 NonePRS47 Glenmark, Moscow, RussiaPRS48 Novartis Farmacéutica, Mexico, MexicoPRS49 NonePRS50 Simpex Pharma, Moscow, RussiaPRS51 Novartis, Barcelona, SpainPRS52 Stallergenes, Antony, FrancePRS53 Nestle Rossiya LLC, Moscow, RussiaPRS54 NonePRS55 ZonMW, The Hague, The NetherlandsPRS56 Stallergenes, Antony, FrancePRS57 Novartis, Hellas SA, GreecePRS58 Novartis Pharmaceuticals, Barcelona, SpainPRS59 Stallergenes, Antony, FrancePRS60 Pulmonx, Inc., Redwood City, CA, USAPRS61 Meda Pharmaceiticals, Inc., Somerset, NJ, USAPRS62 Teva Pharnaceuticals Europe B.V, Amsterdam, The NetherlandsPRS63 Novartis, East Hannover, NJ, USAPRS64 Mundipharma International Ltd., Cambridge, UKPRS65 MERCK S.L, Madrid, SpainPRS66 Meda Pharmaceuticals, Somerset, NJ, USAPRS67 Ministerio de Sanidad, Madrid, SpainPRS68 Consejeria de Salud Junta de Andalucía, Sevilla, SpainPRS69 TEVA, Amsterdam, The NetherlandsPRS70 Boehringer Ingelheim, Ingelheim, GermanyPRS71 Almirall, S.A., Barcelona, SpainPRS72 EXACT-PRO Initiative, Bethesda, MD, USAPRS73 Forest Research Institute, Inc., Jersey City, NJ, USA;

Almirall, S.A., Barcelona, SpainPRS74 Biogen Idec, Cambridge, MA, USAPRS75 NonePRS76 NonePRS77 CHIESI España SA, Malaga, SpainPRS78 NonePRS79 ALK-Abelló A/S, Hørsholm, DenmarkPRS80 NonePRS81 GlaxoSmithKline, Uxbridge, UKPRS82 Novartis Hellas, Metamorfosi, Attica, GreecePRS83 NonePRS84 Boehringer Ingelheim, Prague, Czech RepublicPRS85 Center for Clinical and Translational Science, Burlington, VT, USAPRS86 NonePRS87 GlaxoSmithKline, Madrid, SpainPRS88 NonePRS89 Pfi zer Japan, Tokyo, JapanPR1 National Institute of Public Health and the Environment, Bilthoven,

The NetherlandsPR2 Janssen-Cilag Ltd., High Wycombe, UKPR3 NonePR4 The EuroQol Group, Rotterdam, The NetherlandsPSS1 Novartis Pharma AG, Basel, SwitzerlandPSS2 Tissue Therapies Ltd., Brisbane, AustraliaPSS3 Novartis, Istanbul, TurkeyPSS4 Novartis, Hellas SA, GreecePSS5 Mölnlycke Health Care Kft, Budapest, HungaryPSS6 NonePSS7 NonePSS8 Smith & Nephew Biotherapeutics, Fort Worth, TX, USAPSS9 NonePSS10 The Medicines Company, Parsippany, NJ, USAPSS12 Singapore Eye Research Institute, Singapore, SingaporePSS13 Dutch Burn Foundation, Beverwijk, The NetherlandsPSS14 Novartis Farmaceutica S.A., Barcelona, SpainPSS15 Novartis Farmaceutica, Barcelona, SpainPSS16 Novartis, Istanbul, TurkeyPSS17 Novartis Hellas, Athens, GreecePSS18 NonePSS19 Novartis Ireland, Dublin, IrelandPSS20 NonePSS21 The Ministry of Science and Education of the Republic of Serbia,

Grant N°175014, Belgrade, Serbia and MontenegroPSS22 Janssen, Panama, PanamaPSS23 Novartis Farmacéutica, Mexico, MexicoPSS24 Pfi zer s.r.o., New York City, NY, USAPSS25 Novartis Pharma AG, Basel, SwitzerlandPSS26 Bayer AB, Solna, SwedenPSS27 Dutch Burns Foundation, Beverwijk, The Netherlands; Fonds

NutsOhra, Amsterdam, The NetherlandsPSS28 NonePSS29 Pfi zer, New York City, NY, USA

REFERENCE CODE

FINANCIAL SUPPORT

PSS30 Beijing Novartis Pharma Ltd., Beijing, ChinaPSS31 Beijing Novartis Pharma Ltd., Beijing, ChinaPSS32 NIHR HTA 12/71, Southampton, UK; NIHR HTA 12/71,

Southampton, UKPSS33 LEO Pharma Oy, Vantaa, FinlandPSS34 Novartis, Basel AG, SwitzerlandPSS35 NonePSS36 Cochlear AG, Basel, SwitzerlandPSS37 NonePSS38 Pfi zer Pharmaceuticals Korea Ltd., Seoul, South KoreaPSS39 NIHR, London, UKPSS40 Novartis AG, Basel, SwitzerlandPSS41 Leo Pharma Sweden, Malmö, SwedenPSS42 Novartis Pharma AG, Basel, SwitzerlandPSS43 Riemser Pharma GmbH, Greifswald - Insel Riems, GermanyPSS44 NonePSS45 NonePSS46 Novartis Farmaceutica, Barcelona, SpainPSS47 NonePSS48 Bayer Pharma AG, Berlin, GermanyPSS49 NonePSS50 NonePSS51 Novartis Farmaceutica S.A., Barcelona, SpainPSS52 National Health and Medical Research Council, Canberra,

AustraliaPSS53 NonePSS54 Quintiles, Durham, NC, USAPSS55 NonePSS56 NonePSS57 NonePSS58 NonePSS59 NonePSY1 NonePSY2 Roche Pharma, Madrid, SpainPSY3 AbbVie Canada, St-Laurent, QC, CanadaPSY4 UCB Pharma, Brussels, BelgiumPSY5 NonePSY6 F. Hoffmann–La Roche, Basel, SwitzerlandPSY7 NonePSY8 Productos Medix SA de CV, Mexico City, MexicoPSY9 Pfi zer México SA de CV, Ciudad de México, MexicoPSY10 NonePSY11 NonePSY12 Novartis Farma – Produtos Farmacêuticos S.A., Lisbon, PortugalPSY13 NonePSY14 NonePSY15 Janssen-Cilag GmbH, Neuss, GermanyPSY16 MSD France, Courbevoie, FrancePSY17 MSD France, Courbevoie, FrancePSY18 NonePSY20 Covidien, Arnold, MO, USAPSY21 NonePSY22 BioMarin, Dubin, Ireland; Alexion, Cheshire, CT, CT, USAPSY24 The Netherlands Organization for Health Research and

Development, the Hague, The NetherlandsPSY25 MundiPharma International, Cambridge, UKPSY26 NonePSY27 NonePSY28 Astellas Pharma, Madrid, SpainPSY29 NonePSY30 NRF, Pretoria, South AfricaPSY31 Novartis Hellas SA, Metamorfosis, GreecePSY32 Takeda Farmacéutica España, Madrid, SpainPSY33 NonePSY34 NRF, Pretoria, South AfricaPSY35 Purdue Pharma, Stamford, CT, USAPSY36 Novartis, East Hanover, NJ, USAPSY37 Purdue Pharma, Stamford, CT, USAPSY38 Novartis, East Hanover, NJ, USAPSY39 NonePSY40 NonePSY41 NonePSY42 Novartis Hellas, Athens, GreecePSY43 NonePSY44 NonePSY45 UCB Pharma, Brussels, BelgiumPSY46 GlaxoSmithKline, Halandri, Greece; GlaxoSmithKline, Brentford, UKPSY47 AMGEN BRAZIL, São Paulo, BrazilPSY48 Eisai, Inc., Woodcliff Lake, NJ, USAPSY49 Otsuka Pharmaceutical Development & Commercialization,

Princeton, NJ, USAPSY50 Otsuka Pharmaceutical Development & Commercialization,

Princeton, NJ, USAPSY51 LFB - Laboratoire Francais Du Fractionnement Et Des

Biotechonologies, Les Ulis, Courtaboeur, FrancePSY52 NonePSY53 GSK, Tres Cantos (Madrid), Spain

Page 13: Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A699

REFERENCE CODE

FINANCIAL SUPPORT

PSY54 Roche Farmacêutica Química, Lda., Amadora, PortugalPSY55 National Institute for Health Research Collaboration for Leadership

in Applied Health Research and Care for South Yorkshire (NIHR CLAHRC SY), Sheffi eld, UK

PSY56 Astellas Pharma Europe Ltd., Chertsey, UKPSY57 Bayer, Mijdrecht, The NetherlandsPSY58 Grünenthal, Aachen, GermanyPSY59 Productos Medix SA de CV, Mexico City, MexicoPSY60 Psicofarma, Mexico City, MexicoPSY61 NonePSY62 GSK Spain, Tres Cantos - Madrid, SpainPSY63 Amgen Biofarmacêutica, Oeiras, PortugalPSY64 GlaxoSmithKline, Halandri, GreecePSY65 Pfi zer Portugal, Porto Salvo, PortugalPSY66 Amgen s.r.o., Prague, Czech RepublicPSY67 Pfi zer Japan Inc., Tokyo, JapanPSY68 NonePSY69 Baxter Slovakia s.r.o., Bratislava, Slovak RepublicPSY70 Psicofarma, Mexico City, MexicoPSY71 NonePSY72 NonePSY73 GSK, Tres Cantos (Madrid), SpainPSY74 Celgene, Summit, NJ, USAPSY75 NonePSY76 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAPSY77 Vertex Pharmaceuticals Incorporated, Boston, MA, USAPSY78 Eisai, Inc., Woodcliff Lake, NJ, USAPSY79 Janssen Research & Development, Spring House, PA, USAPSY80 Bayer Pharma, Berlin, GermanyPSY81 Pfi zer Pharmaceuticals Korea Ltd., Seoul, South KoreaPSY82 Forest Research Institute, Jersey City, NJ, USAPSY83 Forest Research Institute, Jersey City, NJ, USAPSY84 Mapi, Lyon, FrancePSY85 NonePSY86 NonePSY87 Merck, Sharp & Dohme, Madrid, SpainPSY88 Merck, Sharp & Dohme, Madrid, SpainPSY89 F. Hoffmann-La Roche Ltd., Basel, SwitzerlandPSY90 Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San

Francisco, CA, USAPSY91 Pfi zer Pharmaceuticals Korea Ltd., Seoul, South KoreaPSY92 NonePSY93 NonePSY94 European Union Health Programme [grant A101205], Brussels,

BelgiumPSY95 Arthritis Research UK charity, Chesterfi eld, UKPSY96 Italian Ministry of Public Education, Roma, ItalyPSY97 NonePSY98 NonePSY99 NonePSY100 NonePSY101 NonePSY102 NonePSY103 NonePSY104 NonePSY105 NonePSY106 European Commission, Brussels, Belgium

REFERENCE CODE

FINANCIAL SUPPORT

PSY107 European Commission, Brussels, BelgiumPSY108 NonePSY109 NonePSY110 Actelion Hellas S.A., Marousi, Athens, GreecePSY111 Astrazeneca, Wilmington, DE, USAPSY112 United Therapeutics, Research Triangle Park, NC, USAPSY113 NonePSY114 Novartis Pharma B.V., Arnhem, The NetherlandsPSY115 NonePSY117 NonePSY118 NonePSY119 NonePSY120 NonePSY121 Faculty of Medicine, Nis, YugoslaviaPUK1 Astellas Pharma Europe Ltd., Chertsey, UKPUK2 National Science Council, Taipei, Taiwan; Taipei Wan Fang

Hospital, Taipei, TaiwanPUK3 NonePUK4 Universiti Teknologi Mara, Selangor, MaldivesPUK5 NonePUK6 Roche, Moscow, RussiaPUK7 Fresenius Kabi, Moscow, RussiaPUK8 Allergan Holdings Ltd., Marlow, UKPUK10 NonePUK11 Health Research Board, Dublin, IrelandPUK12 Eli Lilly and Company, Indianapolis, IN, USAPUK13 NIHR, London, UKPUK14 Wellspect HealthCare, Göteborg, SwedenPUK15 Amgen Hellas, Athens, GreecePUK16 Astellas Pharma Europe Ltd., Chertsey, UKPUK17 Astellas Pharma Canada Inc., Markham, ON, CanadaPUK18 NonePUK19 NonePUK20 Novartis Farmacéutica, Mexico, MexicoPUK21 Allergan Holdings Ltd., Marlow, UKPUK22 Allergan Holdings Ltd., Marlow, UKPUK23 Fresenius Kabi Asia Pacifi c Limited, Hong Kong, Hong KongPUK24 NonePUK25 Sanofi , Barcelona, SpainPUK26 Allergan, Marlow, UKPUK27 Astellas Pharma France, Levallois Perret, FrancePUK28 Astellas Pharma Canada, Inc., Markham, ON, CanadaPUK29 NonePUK30 NonePUK31 NonePUK32 Astellas Pharma Europe Ltd., Chertsey, UKPUK33 CSIC, Montevideo, UruguayPUK34 Astellas Pharma Europe Ltd., Chertsey, UKPUK35 NoneQA1 Costello Medical Consulting Ltd., Cambridge, UKQA2 MRC, London, UKQA3 Lilly S.A., Madrid, SpainQA4 NoneQL1 Eli Lilly and Company, Windlesham, Surrey, UKQL2 NoneQL3 Belgian Stroke Council, Hasselt, BelgiumQL4 County Council of Östergötland, Linköping, Sweden


Top Related